Tags

Type your tag names separated by a space and hit enter

Efficacy and safety of tonabersat, a gap-junction modulator, in the acute treatment of migraine: a double-blind, parallel-group, randomized study.
Cephalalgia 2009; 29 Suppl 2:7-16C

Abstract

The ability of tonabersat to relieve the symptoms of migraine attacks with or without aura was evaluated in a randomized, double-blind, placebo-controlled, multicentre, parallel-group study. Patients received 20 or 40 mg of tonabersat, or 50 mg of sumatriptan (positive control), or placebo at the onset of a moderate or severe attack. Headache intensity, relief and recurrence were recorded for 24 h after dosing. On the basis of primary or secondary efficacy measures, tonabersat did not provide a clinically or statistically significant advantage over placebo. Tonabersat generally was well tolerated and had no effect on vital signs, electrocardiogram recordings or laboratory values. The lack of efficacy may be a function of the slow absorption of tonabersat. As a consequence of slow absorption, daily administration of tonabersat as prophylaxis for migraine attacks is under investigation in ongoing studies.

Authors+Show Affiliations

Gothenburg Migraine Clinic, Gothenburg, Sweden. carl.dahlof@migraineclinic.seNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19723121

Citation

Dahlöf, C G H., et al. "Efficacy and Safety of Tonabersat, a Gap-junction Modulator, in the Acute Treatment of Migraine: a Double-blind, Parallel-group, Randomized Study." Cephalalgia : an International Journal of Headache, vol. 29 Suppl 2, 2009, pp. 7-16.
Dahlöf CG, Hauge AW, Olesen J. Efficacy and safety of tonabersat, a gap-junction modulator, in the acute treatment of migraine: a double-blind, parallel-group, randomized study. Cephalalgia. 2009;29 Suppl 2:7-16.
Dahlöf, C. G., Hauge, A. W., & Olesen, J. (2009). Efficacy and safety of tonabersat, a gap-junction modulator, in the acute treatment of migraine: a double-blind, parallel-group, randomized study. Cephalalgia : an International Journal of Headache, 29 Suppl 2, pp. 7-16. doi:10.1111/j.1468-2982.2009.01975.x.
Dahlöf CG, Hauge AW, Olesen J. Efficacy and Safety of Tonabersat, a Gap-junction Modulator, in the Acute Treatment of Migraine: a Double-blind, Parallel-group, Randomized Study. Cephalalgia. 2009;29 Suppl 2:7-16. PubMed PMID: 19723121.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy and safety of tonabersat, a gap-junction modulator, in the acute treatment of migraine: a double-blind, parallel-group, randomized study. AU - Dahlöf,C G H, AU - Hauge,A W, AU - Olesen,J, PY - 2009/9/3/entrez PY - 2009/9/3/pubmed PY - 2009/11/18/medline SP - 7 EP - 16 JF - Cephalalgia : an international journal of headache JO - Cephalalgia VL - 29 Suppl 2 N2 - The ability of tonabersat to relieve the symptoms of migraine attacks with or without aura was evaluated in a randomized, double-blind, placebo-controlled, multicentre, parallel-group study. Patients received 20 or 40 mg of tonabersat, or 50 mg of sumatriptan (positive control), or placebo at the onset of a moderate or severe attack. Headache intensity, relief and recurrence were recorded for 24 h after dosing. On the basis of primary or secondary efficacy measures, tonabersat did not provide a clinically or statistically significant advantage over placebo. Tonabersat generally was well tolerated and had no effect on vital signs, electrocardiogram recordings or laboratory values. The lack of efficacy may be a function of the slow absorption of tonabersat. As a consequence of slow absorption, daily administration of tonabersat as prophylaxis for migraine attacks is under investigation in ongoing studies. SN - 1468-2982 UR - https://www.unboundmedicine.com/medline/citation/19723121/Efficacy_and_safety_of_tonabersat_a_gap_junction_modulator_in_the_acute_treatment_of_migraine:_a_double_blind_parallel_group_randomized_study_ L2 - http://journals.sagepub.com/doi/full/10.1111/j.1468-2982.2009.01975.x?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -